Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711477 · ClinicalTrials.gov registry record · Phase 2
A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00711477 is a Phase 2 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 46 participants.
The verdict
NCT00711477, a Phase 2 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.
Interventions
- DRUG Placebo
- DRUG Naltrexone SR 32 mg/bupropion SR 360 mg/day
- OTHER fMRI scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711477
The ClinicalTrials.gov registry entry for NCT00711477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00711477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711477 about?
NCT00711477 is a clinical study titled "A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects". The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.
What is the current status of trial NCT00711477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2008-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00711477?
The interventions under investigation include: Placebo (DRUG), Naltrexone SR 32 mg/bupropion SR 360 mg/day (DRUG), fMRI scan (OTHER).
Who is sponsoring clinical trial NCT00711477?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.